{"name":"BioTheraVision, Inc.","slug":"biotheravision-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"BTV100 Mid dose","genericName":"BTV100 Mid dose","slug":"btv100-mid-dose","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"phase_2"},{"name":"BTV100 High dose","genericName":"BTV100 High dose","slug":"btv100-high-dose","indication":"Relapsed or refractory B-cell non-Hodgkin lymphoma","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"BTV100 Low dose","genericName":"BTV100 Low dose","slug":"btv100-low-dose","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"BTV100 Mid dose","genericName":"BTV100 Mid dose","slug":"btv100-mid-dose","phase":"phase_2","mechanism":"BTV100 is a monoclonal antibody targeting CD19.","indications":["Relapsed or refractory diffuse large B-cell lymphoma","Relapsed or refractory follicular lymphoma"],"catalyst":""},{"name":"BTV100 High dose","genericName":"BTV100 High dose","slug":"btv100-high-dose","phase":"phase_2","mechanism":"BTV100 is a monoclonal antibody targeting CD19.","indications":["Relapsed or refractory B-cell non-Hodgkin lymphoma","Chronic lymphocytic leukemia"],"catalyst":""},{"name":"BTV100 Low dose","genericName":"BTV100 Low dose","slug":"btv100-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}